Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic.
about
A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoireClinical utilities and biological characteristics of melanoma sentinel lymph nodesA note from history: Landmarks in history of cancer, part 7.Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group.Final trial report of sentinel-node biopsy versus nodal observation in melanoma.Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patientsSentinel node biopsy in melanoma: technical considerations of the procedure as performed at the John Wayne Cancer Institute.Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients.Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients.Basal cell carcinoma over chest wall (sternum) treated with dufourmentel flap: report of a case with review of literatureMultivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases.Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site.The role of sentinel lymph node biopsy in the management of melanomaCurrent management of the axilla in patients with clinically node-negative breast cancer: a nationwide survey of United Kingdom breast surgeonsA multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanomaIntraoperative identification of sentinel lymph node in patients with malignant melanoma.Lymphatic mapping and sentinel lymphadenectomy in primary cutaneous melanoma.Superficial and deep lymph node dissection for stage III cutaneous melanoma: clinical outcome and prognostic factors.Current surgical management of melanoma.Dose optimization for near-infrared fluorescence sentinel lymph node mapping in patients with melanomaImpact and outcomes of routine microstaging of sentinel lymph nodes in breast cancer: significance of the pN0(i+) and pN1mi categories.Lymph node ratio predicts disease-specific survival in melanoma patients.Implementing sentinel lymph node biopsy programs in developing countries: challenges and opportunities.Pathways for cervical metastasis in malignant neoplasms of the head and neck region.Update on the melanoma staging system: the importance of sentinel node staging and primary tumor mitotic rate.Analysis of regional recurrence after negative sentinel lymph node biopsy for head and neck melanoma.Sentinel lymph node biopsy in melanoma: controversies and current guidelines.Recent developments in the medical and surgical treatment of melanoma.The role of FDG-PET/CT in preoperative staging of sentinel lymph node biopsy-positive melanoma patients.The competent sentinel node: an association with an axillary presentation and an occult or a small primary invasive breast carcinoma.Epidemiology, management and survival outcomes of primary cutaneous melanoma: a ten-year overview.Management of Conjunctival Melanoma: Critical Assessment of Sentinel Lymph Node Biopsy.Update on active specific immunotherapy with melanoma vaccines.Melanoma induces immunosuppression by up-regulating FOXP3(+) regulatory T cells.Prognostic evaluation of cutaneous malignant melanoma based on the pTNM classification.Another brick in the wall: toward a better understanding of melanoma of unknown primary.Diversity of stage III melanoma in the era of sentinel lymph node biopsy.A new American Joint Committee on Cancer staging system for cutaneous melanoma.Ultrathin primary is a marker for worse prognosis in lymph node-positive cutaneous melanoma.Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression.
P2860
Q24654139-C341A7F6-C700-404C-9626-B4AFDE5F035FQ26747723-C42A1ED5-2344-4AC3-825A-03DABD622102Q30931923-CC7EC8EC-568B-4323-A382-71A5B853C815Q33752235-7B0B42B8-9505-444E-9EF4-383AD695C58AQ33760173-B4E8A607-F4F6-4178-A11E-83972649F525Q33797051-3A54DF3B-6C58-4A9D-8559-8D036A2FA84EQ33890196-DE885F50-1A8F-4879-BC79-B1AB3856C120Q33954883-BF5F20BE-1D40-4745-A44A-F8227EF98D04Q34093600-F02BB176-1AA9-4886-8BE8-9FD72E030A76Q34209883-3C226BE2-E420-4A38-8483-F4B7861FF4B7Q34315676-7BF9803C-0C4D-47FF-A6A0-878DB009C16BQ34446657-6492450D-E839-4D05-9781-311B6F00FB44Q34584396-7FC27D63-249D-47AF-AA5D-CE7F5DB8D114Q35652997-A25EDF24-8E97-4503-91F3-68EBC6FE2ED3Q36201336-82C13192-5BDE-46C5-8AAD-AC9E656C6241Q36421679-04F65551-70C4-49EF-B890-7759D35B4396Q36532123-7BD47468-AAAC-4788-A163-AC8921ACF69FQ36648843-FE7BA21C-F903-4A99-8188-974063D971A6Q36668237-A083265A-9D0C-4EC4-A01F-E746D5DA9FBBQ36715613-1615FA81-F1C8-4AEA-8400-C58FD926CD0FQ37307652-9E3B6F44-FBED-4889-A8A0-A21813984362Q37370769-10FA2A9B-27B8-4C1B-9947-71E9F071E4A2Q37832409-9AB202E0-85BC-48F8-84D1-EB01407DD421Q37919776-7C8FCD8B-6D60-41DA-AD17-0B125002BA42Q37920834-D4BF08A9-DF2C-4BB0-A47A-25D653673FB4Q38030894-3F88537D-10F1-4541-A100-5C3F431014A0Q38190113-064961B9-E4AB-4074-B121-FBA1ED0713ECQ38200004-93C8F03B-F11F-4865-BCAD-B221F5483770Q39317681-A93772E3-9807-41CB-8DA1-31526BF1FF07Q39860307-682AD720-423E-4B5C-91B7-E026E752DDF9Q40520492-2EEE6946-67E0-4B0C-8439-039A529337D7Q40709215-7CED372F-3539-44BE-8B83-E4802AC5B8EBQ41589321-1716F0E0-EBEE-4DAB-BC6E-D7D94199DE7BQ42106687-5DEEC7E3-19F9-4A06-A216-8C709C304FFBQ43786951-6207E96C-660F-43EF-9E2E-A2F56C8A316BQ44128741-E30CE576-872E-48BA-B46D-BC7C7F408660Q44714604-0C1CDAA4-D91A-479C-8A3F-82E3B23AE012Q44869575-D33408AB-D312-4CBC-81B3-3459D31A2B54Q45102326-2188D852-A9C4-4A00-B1DD-1D150EAEA4CAQ45201798-6F804D3E-2086-4DE9-B428-1E5A14C4111E
P2860
Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 1991
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Improved long-term survival af ...... the John Wayne Cancer Clinic.
@en
Improved long-term survival af ...... the John Wayne Cancer Clinic.
@nl
type
label
Improved long-term survival af ...... the John Wayne Cancer Clinic.
@en
Improved long-term survival af ...... the John Wayne Cancer Clinic.
@nl
prefLabel
Improved long-term survival af ...... the John Wayne Cancer Clinic.
@en
Improved long-term survival af ...... the John Wayne Cancer Clinic.
@nl
P2093
P1433
P1476
Improved long-term survival af ...... the John Wayne Cancer Clinic.
@en
P2093
P304
491-9; discussion 499-501
P356
10.1097/00000658-199110000-00013
P407
P577
1991-10-01T00:00:00Z